Mark Christianson Sells 10,000 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the transaction, the director owned 20,692 shares in the company, valued at approximately $65,800.56. The trade was a 32.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

NeuroOne Medical Technologies Stock Performance

Shares of NMTC stock remained flat at $3.00 on Thursday. The company had a trading volume of 17,315 shares, compared to its average volume of 40,985. NeuroOne Medical Technologies Corporation has a twelve month low of $2.89 and a twelve month high of $6.96. The company has a market capitalization of $26.11 million, a PE ratio of -3.53 and a beta of 0.54. The stock’s 50 day moving average is $3.88 and its 200 day moving average is $4.40.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $1.86 million during the quarter, compared to the consensus estimate of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. As a group, analysts predict that NeuroOne Medical Technologies Corporation will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after acquiring an additional 375,639 shares during the period. Renaissance Technologies LLC boosted its stake in shares of NeuroOne Medical Technologies by 10.2% in the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after purchasing an additional 70,428 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of NeuroOne Medical Technologies during the fourth quarter worth $143,000. Virtu Financial LLC bought a new stake in NeuroOne Medical Technologies during the third quarter valued at $88,000. Finally, Goldman Sachs Group Inc. acquired a new stake in NeuroOne Medical Technologies during the 1st quarter worth about $84,000. 16.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Weiss Ratings downgraded shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Zacks Research downgraded shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Finally, LADENBURG THALM/SH SH increased their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NeuroOne Medical Technologies has a consensus rating of “Hold” and an average price target of $11.67.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.